We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

GZMK+ CD8+ T Cells Drive Selective Acinar Cell Loss and Interferon Signaling in Sjögren’s Disease

MedXY Editorial Team•Nov 4, 2025•news
CD8 T cellsSjögren's syndrome

Highlight

– Single-cell and spatial transcriptomics identify a previously unrecognized PRR4⁺CST3⁺WFDC2⁻ seromucous acinar population that is selectively depleted in Sjögren’s disease (SjD).
– GZMK⁺CD8⁺ T cells accumulate with disease severity, show a cytotoxic yet sub-lytic program, and spatially co-localize with immune-engaged epithelial cells.
– Functional assays indicate GZMK impairs mitochondrial integrity and triggers interferon signaling in epithelial cells — linking targeted epithelial injury to type I interferon responses and suggesting new therapeutic targets.

Background: clinical context and unmet need

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

TNF-α–Driven Immune-Endothelial Injury Emerges as a Therapeutic Target in Severe Acute PancreatitisSingle-cell analysis of human severe acute pancreatitis identifies TNF-α–induced CD8+ T-cell endothelial injury as a driver of pancreatic microcirculatory failure, supporting TNF-α blockade as a potential targeted therapy.Jun 5, 2026Deep learning classifies focus score and Sjögren’s disease from minor salivary gland biopsies and highlights a CD8+ acinar patternA multicentre deep‑learning model reliably classified biopsy focus score and ACR‑EULAR–defined Sjögren’s disease (AUROC ≈0.88–0.89) and identified a novel CD8+ T‑cell peri‑acinar pattern associated with disease; prospective validation is neDec 1, 2025FcRn blockade with nipocalimab reduces disease activity in moderate‑to‑severe Sjögren’s syndrome: positive phase 2 DAHLIAS resultsIn DAHLIAS, intravenous nipocalimab 15 mg/kg every 2 weeks for 22 weeks significantly reduced ClinESSDAI scores versus placebo in anti‑Ro seropositive patients with moderate‑to‑severe Sjögren’s disease, with a safety profile similar to placNov 27, 2025
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story